Zevra Therapeutics announced that it has joined the Sleep Data Initiative as a founding member. The new data collection platform is led by RARE-X and the Sleep Consortium to provide access to research-grade, patient-owned data to support the acceleration of research and treatment development for sleep disorders. "Marking World Sleep Day today, we are proud to announce this important collaboration and our role as a founding member of this significant initiative to support acceleration and advancement of sleep research programs," said Richard W. Pascoe, Chief Executive Officer of Zevra. "The data being generated by our clinical program for KP1077, our novel therapy intended for the treatment of idiopathic hypersomnia, will support the research and development of effective treatments for rare sleep disorders through the use of this vital platform." RARE-X is a research program and data collection platform sponsored by Global Genes. The platform is currently supporting 83 disease communities, with about 58 percent of participants having reported sleep disturbance as a phenotype. In addition, Zevra Therapeutics announced that U.S. Patent No. 11,505,537 from the United States Patent and Trademark Office was issued for its patent application entitled, "Compositions Comprising Methylphenidate-Prodrugs, Processes of Making and Using the Same." This patent expands Zevra’s intellectual property estate for serdexmethylphenidate, which includes methods of use for methylphenidate conjugates to provide extended release of d-methylphenidate,
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZVRA:
- Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
- Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
- Zevra Therapeutics urges shareholders to vote for all director nominees
- Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
- Zevra Therapeutics reports Q4 EPS (26c), consensus (17c)